Commercial

Charleston Laboratories Creates US Commercial Subsidiary

In January 2017, Charleston announced the formation of Õlas Pharma, Inc., a wholly owned US subsidiary established to conduct commercialization activities for Charleston Laboratories’ pipeline of products. Product commercialization will address significant patient needs such as Opioid-Induced Nausea and Vomiting (OINV) and Migraine-Associated Nausea and Vomiting (MANV).

“The creation of a formal commercial presence has always been a part of Charleston Laboratories’ growth strategy, and it is extremely gratifying to reflect on the hard work and successes that have made this a reality,” said Mr. Paul Bosse, President and Chief Executive Officer at Charleston Laboratories.

-bar-

“The formation of Õlas Pharma lays the groundwork for our direct involvement in the commercialization of our robust pipeline of drug candidates.”